BRENDA DELEON: Open Payments
NPI 1205406576 · KEARNEY, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$538 in 65 payments from 8 companies in 2025. Trend: 2023 $916 · 2024 $770 · 2025 $538
Food & beverage: $538
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 56 | $382 |
| AstraZeneca Pharmaceuticals LP | 1 | $35 |
| Kerecis Limited | 1 | $26 |
| Astellas Pharma US Inc | 1 | $26 |
| GENZYME CORPORATION | 1 | $24 |
| Phathom Pharmaceuticals, Inc. | 3 | $18 |
| Lilly USA, LLC | 1 | $14 |
| Novartis Pharmaceuticals Corporation | 1 | $14 |
Products named: VRAYLAR, UBRELVY, QULIPTA, BREZTRI, Kerecis SurgiClose, Veozah, DUPIXENT, VOQUEZNA.
Industry payments across NE — which companies pay providers there.
